Lv22
180 积分 2024-02-19 加入
中心病理独立评审委员会在临床试验中运行的规范化共识
21小时前
已完结
中心病理独立评审委员会在临床试验中运行的规范化共识
21小时前
已关闭
中心病理独立评审委员会在临床试验中运行的规范化共识
21小时前
已关闭
中心病理独立评审委员会在临床试验中运行的规范化共识
21小时前
已关闭
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
2个月前
已完结
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
4个月前
已完结
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
5个月前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
5个月前
已完结
Lessons from TROPiCS-04: 'safety-first' for success in late-stage clinical trials
6个月前
已完结
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials
6个月前
已完结
皖公网安备34019202002308
